TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Bertrand, Florie ^a,b   Montfort, Anne ^a,b   Marcheteau, Elie ^a,b,c,d   Imbert, Caroline ^a,b,c,d   Gilhodes, Julia ^e   Filleron, Thomas ^e   Rochaix, Philippe ^e   Andrieu Abadie, Nathalie ^a,b   Levade, Thierry ^a,b,c,d,f   Meyer, Nicolas ^a,c,d,g   Colacios, Céline ^a,b,c,d   Ségui, Bruno ^a,b,c,d  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b Equipe Labellisee Ligue Contre le Cancer and Laboratoire D'Excellence Toulouse Cancer TOUCAN   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d UNIVERSITÉ DE TOULOUSE   (France)

^e Institut Universitaire du Cancer de Toulouse   (France)

^f CHU PURPAN   (France)

^g SERVICE DE PNEUMOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; GAMMA INTERFERON; GRANZYME B; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; KI 67 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; CD274 PROTEIN, MOUSE; HAVCR2 PROTEIN, HUMAN; HAVCR2 PROTEIN, MOUSE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANTIBODY; APOPTOSIS; CANCER; CELLS AND CELL COMPONENTS; GENE; IMMUNE RESPONSE; IMMUNE SYSTEM; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL MELANOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR VOLUME; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; DRUG RESISTANCE; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENETICS; MELANOMA; METABOLISM; SKIN TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IPILIMUMAB; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, ANIMAL; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85039172691     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-02358-7     Document Type: Article

References (44)

1. Bertrand, F., Colacios, C. & Segui, B. TNF-R1, an immune checkpoint in melanoma? Genes Cancer 6, 369-370 (2015).
2. Bertrand, F. et al. Targeting TNF alpha as a novel strategy to enhance CD8+ T cell-dependent immune response in melanoma? Oncoimmunology 5, e1068495 (2016).
3. Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 9, 361-371 (2009).
4. Carswell, E. A. et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666-3670 (1975).
5. Ratner, A. & Clark, W. R. Role of TNF-alpha in CD8+ cytotoxic T lymphocyte-mediated lysis. J. Immunol. 150, 4303-4314 (1993).
6. Chopra, M. et al. Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis. Carcinogenesis 34, 1296-1303 (2013).
7. Okubo, Y., Mera, T., Wang, L. & Faustman, D. L. Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci. Rep. 3, 3153 (2013).
8. Schioppa, T. et al. B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc. Natl. Acad. Sci. USA 108, 10662-10667 (2011).
9. Zhao, X. et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J. Clin. Invest. 122, 4094-4104 (2012).
10. Sade-Feldman, M. et al. Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 38, 541-554 (2013).
11. Beyer, M. et al. Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection. Nat. Immunol. 17, 593-603 (2016).
12. Chen, X., Baumel, M., Mannel, D. N., Howard, O. M. & Oppenheim, J. J. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+ CD25+ T regulatory cells. J. Immunol. 179, 154-161 (2007).
13. Zheng, L. et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377, 348-351 (1995).
14. Bertrand, F. et al. Blocking tumor necrosis factor alpha enhances CD8 T-cell-dependent immunity in experimental melanoma. Cancer Res. 75, 2619-2628 (2015).
15. Donia, M. et al. Aberrant expression of MHC class II in melanoma attracts inflammatory tumor-specific CD4+ T- cells, which dampen CD8+ T-cell antitumor reactivity. Cancer Res. 75, 3747-3759 (2015).
16. Landsberg, J. et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490, 412-416 (2012).
17. Lim, S. O. et al. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 30, 925-939 (2016).
18. Larkin, J. et al Combined nivolumab and Ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
19. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330 (2015).
20. Robert, C. et al Pembrolizumab versus Ipilimumab in advanced melanoma.N. Engl. J. Med. 372, 2521-2532 (2015).
21. Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974-1982 (2015).
22. Koyama, S. et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 7, 10501 (2016).
23. Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827-837 (2016).
24. Spain, L., Diem, S. & Larkin, J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat. Rev. 44, 51-60 (2016).
25. Rizvi, N. A. et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16, 257-265 (2015).
26. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627-1639 (2015).
27. Sabatos, C. A. et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat. Immunol. 4, 1102-1110 (2003).
28. Fourcade, J. et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207, 2175-2186 (2010).
29. Borghi, A., Verstrepen, L. & Beyaert, R. TRAF2 multitasking in TNF receptor-induced signaling to NF-kappaB, MAP kinases and cell death. Biochem. Pharmacol. 116, 1-10 (2016).
30. Yoon, S. J. et al. Activation of mitogen activated protein kinase-Erk kinase (MEK) increases T cell immunoglobulin mucin domain-3 (TIM-3) transcription in human T lymphocytes and a human mast cell line. Mol. Immunol. 48, 1778-1783 (2011).
31. Mujib, S. et al. Antigen-independent induction of Tim-3 expression on human T cells by the common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. J. Immunol. 188, 3745-3756 (2012).
32. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681-1696 (2015).
33. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
34. Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707-723 (2017).
35. Daud, A. I. et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Invest. 126, 3447-3452 (2016).
36. Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187-2194 (2010).
37. Ngiow, S. F. et al. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71, 3540-3551 (2011).
38. Zhu, C. et al. An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat. Commun. 6, 6072 (2015).
39. Zingg, D. et al. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 20, 854-867 (2017).
40. Reinhardt, J. et al. MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy. Cancer Res. 77, 4697-4709 (2017).
41. Galluzzi, L. et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell. Death. Differ. 22, 58-73 (2015).
42. Porgador, A., Feldman, M. & Eisenbach, L. H-2Kb transfection of B16 melanoma cells results in reduced tumourigenicity and metastatic competence. J. Immunogenet. 16, 291-303 (1989).
43. Pequeux, C. et al. Stromal estrogen receptor-alpha promotes tumor growth by normalizing an increased angiogenesis. Cancer Res. 72, 3010-3019 (2012).
44. Sheehan, K. C. et al. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J. Exp. Med. 181, 607-617 (1995).